犬關節炎治療市場- 依治療類型（藥物{NSAIDs}、補充劑{葡萄糖胺}、外科手術）、關節炎類型（骨關節炎、骨軟骨病、類風濕性關節炎、創傷性關節炎）、全球預測（2024 - 2032）

犬關節炎治療市場規模預計在2024年至2032年間複合年成長率將超過4.7%。這進一步推動了對有效治療的需求，以減輕患病寵物的疼痛並改善其生活品質。根據關節炎基金會的數據，每五隻狗就有一隻患有犬類關節炎。寵物主人越來越意識到關節炎的症狀和早期介入的重要性，導致對獸醫諮詢、診斷服務和治療解決方案的強烈需求。

獸醫領域不斷發展的技術進步和創新也影響著市場的成長。新藥的開發，包括非類固醇類抗發炎藥物（NSAID）、緩解骨關節炎藥物（DMOAD）和幹細胞療法等再生療法，為獸醫有效治療犬類疾病提供了更廣泛的選擇關節炎。物理療法、水療法和關節保健補充劑等替代療法的日益普及和普及將進一步擴大市場成長。

犬關節炎治療行業分為治療類型、關節炎類型和地區。

根據治療類型，由於獸醫外科技術的進步和外科干預措施的接受度不斷提高，外科手術治療類型細分市場的市場規模預計在 2024 年至 2032 年期間將出現顯著的複合年成長率。關節鏡檢查、關節手術和矯正截骨術等手術變得越來越普遍，因為它們可以顯著改善患有晚期關節炎的狗的活動能力和生活品質。這些手術得到更好的診斷工具和術後護理的支持，以提高其成功率和結果。

由於人們對犬類自體免疫關節炎疾病的日益認知以及針對這些疾病的標靶療法的開發，預計到2032 年，類風濕性關節炎類型領域的犬關節炎治療行業將錄得可觀的成長率。類風濕性關節炎雖然在狗身上比骨關節炎少見，但如果不及時治療，可能會導致嚴重的疼痛和關節損傷。隨著獸醫學的發展，人們對狗自身免疫性關節炎的機制的了解不斷加深，從而導致了新的治療方案的開發，例如緩解疾病的藥物和免疫抑制劑。

由於確保獸藥安全性和有效性的嚴格監管標準以及不斷成長的微創手術，歐洲犬關節炎治療行業預計將在 2024 年至 2032 年期間持續成長。完善的獸醫基礎設施和高寵物擁有率正在增加對專業關節炎治療的需求。對預防性治療的高度重視以及歐洲寵物主人對關節炎治療策略的認知不斷增強也推動了該區域市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 提高人們對犬類健康的認知
    • 關節炎及相關疾病病例不斷增加
    • 治療技術的進步
  • 產業陷阱與挑戰
    • 治療費用高
• 成長潛力分析
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

• 主要趨勢
• 藥品
  • 非類固醇類抗發炎藥 (NSAID)
  • 皮質類固醇
  • 鴉片類止痛藥
  • 其他藥品
• 補充品
  • 葡萄糖胺
  • 軟骨素
  • 甲磺醯甲烷
  • 其他補充劑
  • 藥物和補充劑市場（按給藥途徑）
    • 口服
    • 可注射
    • 其他給藥途徑
  • 藥品和補充劑市場（按配銷通路）
    • 獸醫院藥房
    • 零售藥局
    • 網路藥局
• 外科手術
• 其他治療類型

第 6 章：市場估計與預測：按關節炎類型，2021 - 2032

• 主要趨勢
• 骨關節炎
• 骨軟骨病
• 類風濕關節炎
• 創傷性關節炎

第 7 章：市場估計與預測：按地區分類，2021 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 中東和非洲其他地區

第 8 章：公司簡介

• American Regent, Inc.
• Bayer AG
• Boehringer Ingelheim Animal Health
• CEVA Santé Animale
• Dechra Pharmaceuticals PLC
• Elanco Animal Health
• Nutramax Laboratories Veterinary Sciences, Inc.
• Vetoquinol SA
• VetStem, Inc.
• Virbac
• Zoetis Inc.

Canine Arthritis Treatment Market size is expected to register over 4.7% CAGR between 2024 and 2032. With the rising number of aging dogs, the incidence of arthritis, which is a common disease in older dogs, is increasing. This is further driving the demand for effective treatments to relieve pain and improve the quality of life of the sick pets. As per Arthritis Foundation, canine arthritis affects one out of every five dogs. Pet owners have grown increasingly aware of the symptoms of arthritis and the importance of early intervention, leading to the strong demand for veterinary consultations, diagnostic services, and treatment solutions.

Growing technological advancements and innovations in veterinary medicine are also influencing the market growth. The development of new drugs, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying osteoarthritis drugs (DMOADs), and regenerative therapies, such as stem cell therapy, is offering veterinarians a wider range of options for effective treatment of canine arthritis. The increasing availability and popularity of alternative therapies like physical therapy, hydrotherapy and joint health supplements will further expand the market growth.

The canine arthritis treatment industry is classified into treatment type, arthritis type and region.

Based on treatment type, the market size from the surgical procedure treatment type segment is slated to witness significant CAGR during 2024-2032, owing to advancements in veterinary surgical techniques and the increasing acceptance of surgical interventions. Procedures, such as arthroscopy, joint surgery and corrective osteotomies are becoming more common as they significantly improve mobility and quality of life in dogs with advanced arthritis. These operations are supported by better diagnostic tools and post-operative care for improving their success and results.

Canine arthritis treatment industry from the rheumatoid arthritis type segment is predicted to record decent growth rate through 2032, driven by the increasing recognition of autoimmune arthritis conditions in dogs and the development of targeted therapies to address them. Rheumatoid arthritis, although less common in dogs than osteoarthritis, can cause severe pain and joint damages if left untreated. With developments in veterinary medicine, understanding of the mechanisms underlying autoimmune arthritis in dogs is increasing, leading to the development of new treatment options, such as disease-modifying drugs and immunosuppressants.

Europe canine arthritis treatment industry is poised to depict sustained growth during 2024-2032, attributed to stringent regulatory standards for ensuring the safety and efficacy of veterinary pharmaceuticals along with the growing minimally invasive surgeries. The well-established veterinary infrastructure and high pet ownership rate are increasing the demand for specialized arthritis treatment. The strong emphasis on preventive treatment and the growing awareness of European pet owners about arthritis treatment strategies are also fueling the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing awareness regarding canine health
    • 3.2.1.2 Growing cases of arthritis and related disorders
    • 3.2.1.3 Advancement in technology for treatment
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Drugs
  • 5.2.1 Non-steroidal anti-inflammatory drugs (NSAID's)
  • 5.2.2 Corticosteroids
  • 5.2.3 Opioid pain relievers
  • 5.2.4 Other drugs
• 5.3 Supplements
  • 5.3.1 Glucosamine
  • 5.3.2 Chondroitin
  • 5.3.3 Methylsulfonylmethane
  • 5.3.4 Other supplements
  • 5.3.5 Drugs and supplements market, by route of administration
    • 5.3.5.1 Oral
    • 5.3.5.2 Injectable
    • 5.3.5.3 Other routes of administration
  • 5.3.6 Drugs and supplements market, by distribution channel
    • 5.3.6.1 Veterinary hospital pharmacies
    • 5.3.6.2 Retail pharmacies
    • 5.3.6.3 Online pharmacies
• 5.4 Surgical procedures
• 5.5 Other treatment types

Chapter 6 Market Estimates and Forecast, By Arthritis Type, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Osteoarthritis
• 6.3 Osteochondrosis
• 6.4 Rheumatoid arthritis
• 6.5 Traumatic arthritis

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 American Regent, Inc.
• 8.2 Bayer AG
• 8.3 Boehringer Ingelheim Animal Health
• 8.4 CEVA Santé Animale
• 8.5 Dechra Pharmaceuticals PLC
• 8.6 Elanco Animal Health
• 8.7 Nutramax Laboratories Veterinary Sciences, Inc.
• 8.8 Vetoquinol SA
• 8.9 VetStem, Inc.
• 8.10 Virbac
• 8.11 Zoetis Inc.